Business
Novartis Shares Slide After $12B Avidity Drug Fails Its Pivotal Trial
Del-desiran, the lead muscle-disease therapy Novartis bought with Avidity for $12 billion, missed its main goal in myotonic dystrophy — sending the stock to its worst day since 2020.